Compare Gemini Space Station Inc (GEMI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Novartis AG — how do they compare? Gemini Space Station Inc trades at $4.67 (market cap $590.44M), while Novartis AG trades at $152.01 (market cap $287.66B). The key difference: Novartis AG is far larger — about 487.2× Gemini Space Station Inc's market cap, and Novartis AG pays a 3.14% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| GEMI | NVS | |
|---|---|---|
Market Cap | $590.44M | $287.66B |
Sector | Technology | Health |
52-Week High | $32.52 | $168.62 |
52-Week Low | $3.91 | $113.50 |
Enterprise Value | $580.43M | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.69, up 8.06% in the past 24 hours, with a bullish technical signal but weak fundamentals. The company reported a net loss of $582.81 million in 2025 on $179.57 million revenue, with negative profit margins and cash burn from operations. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May-July 2026.
Outlook remains challenged by persistent losses and legal risks, though analyst consensus suggests modest upside to a $5.88 price target. Investment opportunity hinges on execution turnaround, but high operational and litigation risks warrant caution for stock investors.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
